Allergy Therapeutics secures funding for clinical testing of peanut and grass allergies vaccines

Proceeds of GBP 17m will help the allergy firm initiate early-stage clinical testing of a peanut allergy vaccine, while completing a late-stage study of a vaccine for grass allergy.

Photo: /ritzau/AP/Ken Hammond

Allergy Therapeutics has raised a total of GBP 17m from existing shareholders, proceeds that will go to a phase I and subsequent phase II trials of a vaccine against peanut allergy, as well as completing a currently ongoing phase III study of a grass allergy vaccine, a company press release announces.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs